Themis Bioscience
Aug 22, 2019
Themis Bioscience collaborates with Merck; Oncorus raises USD 80 M; GSK files for Japanese approval of anaemia drug
Themis Bioscience forms an Exclusive License and Research Alliance with MSD to Develop Vaccines Themis Bioscience, a vaccine development firm, has collaborated with the MSD, a trademark company of the Merck. The agreement is an exclusive license with MSD for the discovery and development of measles vaccines to f...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
